Sanger Sequencing Market Analysis And Forecast To 2032: By Sequencing (Shotgun Sequencing, Targeted Gene Sequencing, Others), Application (Diagnostics, Biomarkers and Cancer, Reproductive Health, Personalized Medicine, Forensics, and Others), End Use (Aca

The global Sanger Sequencing Market was valued at USD 1.9 Billion in 2022 and it is anticipated to grow up to USD 13.4 Billion by 2032, at a CAGR of 21.4% during the forecast period.

The Sanger technique of DNA sequencing relies on the random incorporation of chain-terminating dideoxynucleotides by DNA polymerase during in vitro DNA replication and uses electrophoresis. However, for smaller-scale initiatives and for validating the outcomes of deep sequencing, the sanger approach is still widely used. It can still create DNA sequence reads of more than 500 nucleotides and maintain accuracy levels around 99.99 percent, giving it an edge over short-read sequencing methods (like Illumina).

Market Trends and Drivers

The market for Sanger's sequencing services is expanding due to technological developments in sequencing methods, benefits of Sanger's sequencing, and an increase in genome mapping initiatives. Additionally, sequencing applications and R&D expenditure boost have added to the market's expansion.
Research and development (R&D) activities
The increased attention that vendors are paying to developing economies like China, India, and Southeast Asia is anticipated to promote market expansion. The market is expected to experience significant growth in the near future as a result of rising R&D spending and a boom in sanger sequencing applications.
Rise in genetic illness
The expanding use of genetic testing on vertebrates and plants, other factors influencing the market's growth include the rising prevalence and familiarity of genetic illnesses and tailored medicine. During the forecast period of 2022 to 2029, a few factors have the potential to propel market expansion.

Market Restraints and Challenges

The lack of compensation due to the strict restrictions for next-generation sequencing research, the lack of skilled professionals or one might even say a still-evolving business, can operate as a restraint on the market's growth.

The report analyses the global Sanger Sequencing Market based on sequencing, application, end-use, and region.
Global Sanger Sequencing Market by Sequencing
By sequencing, the market is segmented into Shotgun Sequencing, Targeted Gene Sequencing, and Others. Shotgun sequencing segment accounted for largest market share in 2022. This is attributed to the shotgun sequencing is a laboratory technique for determining the DNA sequence of an organism's genome. The method involves randomly breaking up the genome into small DNA fragments that are sequenced individually. metagenomic shotgun sequencing workflow offers fully automated soil sample preparation, sequencing, and analysis, to help researchers characterize soil microbial communities. The growth of the global metagenomics sequencing market is majorly driven by growth in demand for drug discovery, clinical diagnostics, and increase in prevalence of genetic disorder. In addition, metagenomic technologies enable the study of microbial communities as entire units without entailing the need of cultivating them. As uncultivability and genomic diversity serve as the two major roadblocks in the advancements of environmental and clinical microbiology, metagenomics has gained immense traction among the healthcare professionals and researchers. The advancement in metagenomics sequencing technologies is projected to increase the growth opportunities for sequencing market.
Global Sanger Sequencing Market by Application
By application, the Sanger Sequencing Market is classified into Diagnostics, Biomarkers, Cancer, Reproductive Health, Personalized Medicine, Forensics, and Others. Of these the oncology segment dominated the market and accounted for the maximum revenue share of xx% in 2021. The technology holds great potential in clinical research and development of cancer diagnostics and therapeutics. Recently, NGS technology has demonstrated the capacity as a high-throughput and an affordable approach in the identification and characterization of clinically actionable genetic variants across numerous genes at an exceptional speed in a single test. Furthermore, the value of these technologies in companion diagnostics and precision medicine is widely recognized by clinicians and companies. In regard to this, in August 2020, the FDA approved the first liquid biopsy companion diagnostic that leverages NGS technology to guide cancer treatment. The Guardant360 CDx assay promotes less invasive testing and the simultaneous mapping of several biomarkers of genomic alterations in the tumor.
Global Sanger Sequencing Market by End-user
Based on end-use. It is segmented into D Academic, Government Research Institutes, Pharmaceutical Companies, Biotechnology Companies, Hospitals, and Clinics. In 2022, research and academic institutes led the market with a revenue share of over 50.0%. The growth is attributed to the increased R&D studies conducted by academic institutes using miRNA sequencing techniques. Moreover, wide acceptability of Sanger technology and NGS in academic and institutional research projects. Besides, a rise in funding and investment programs augment the demand for DNA sequencing products in these entities, resulting in a larger revenue share. For instance, in January 2020, the Intelligence Advanced Research Projects Activity provided USD 23.0 million to the Broad Institute and Harvard University, and DNA Script. The entities are working together to explore the possibility of combining the enzymatic DNA synthesis technology and NGS into a single instrument for more than four years. This consortium further plans to partner with Illumina to utilize its sequencing-by-synthesis technology.

Geographical Analysis of Global Sanger Sequencing Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America dominated the market with a revenue share of over xx% in 2022. This is attributed to the increase in implementation of DNA sequencing across metagenomics applications in this region. In addition, rapid adoption of novel sequencing technologies in this region has contributed to its dominance. Increase in acquisition, product launch, and product approval by key players of this market operate in North America turn, fuels growth of the market. In Asia Pacific, the market is projected to witness a lucrative growth rate throughout the forecast period. Strategic initiatives undertaken by international firms to expand their presence due to the high customer base is expected to create numerous opportunities for regional growth. For instance, in February 2020, GenapSys, a California-based firm, raised USD 75 million to finance the global expansion of its tabletop DNA sequencer to support the control of coronavirus in the region.

Major Players in the Global Sanger Sequencing Market

The key players in the Sanger Sequencing Market  Thermo Fisher Scientific Inc (U.S.), Source BioScience (U.K.), GenScript (U.S.), LGC Limited (U.K.), CeMIA (U.S.),, Quintara Biosciences (U.S.), GenHunter Corporation (U.S.), GENEWIZ (U.S.), , Nucleics (U.K.), SciGenom Labs Pvt. Ltd (India), Microsynth AG (Switzerland), Eurofins Scientific (Luxembourg), LGC Limited (U.K.), among others.

COVID-19 Impact:

The COVID-19 epidemic had an severe negative impact on society and the economy. The pandemic has impacted numerous organisations' supply chains and value chains. The market for sanger sequencing is typical. On the basis of the entire industry, taking into account both the demand side and supply side viewpoints, the impact of the COVID-19 pandemic will be examined. The COVID-19 pandemic has enhanced the usage of miRNA to identify the presence of coronavirus. miRNA biomarkers have potential application to indicate and diagnose the COVID-19 severity. It plays a significant role in immune response, viral proliferation, replication of infected cells, and cardiovascular dysfunction. In addition, plasma recovered from COVID-19 patients is rich in antibodies and antiviral miRNAs. It has been utilized to treat COVID-19-infected patients. This has resulted in increasing research studies that focus on the miRNA sequence analysis from the patient as well as the virus.

Recent Developments:In August 2020, Illumina Inc. launched NovaSeq 6000 v1.5 Reagent Kit, which made the WGS technique more cost-effective and accessible for all the laboratories and reduced the cost to sequence a human genome for USD 600. These new kits can be used across WGS, single-cell genomics, and liquid biopsy techniques.In June 2020, Illumina received Emergency Use Authorization (EUA) from the FDA for its COVIDSeq Test that is used to sequence the full genome of the novel SARS-CoV-2 virus. This test along with high-throughput NovaSeq 6000 hardware of Illumina is capable of processing more than 3,000 samples and offers results within 24 hours.In April 2020, Helix OpCo LLC received EUA for its Helix COVID-19 NGS Test for the detection of SARS-CoV-2 infectionIn February 2020, GenapSys, a California-based firm, raised USD 75 million to finance the global expansion of its tabletop DNA sequencer to support the control of coronavirus in the regionIn June 2019, PerkinElmer, Inc. along with FDNA, an artificial intelligence company, introduced Face2Gene LABS to provide genomic services, in combination with Next-Generation Phenotyping (NGP) technologies for more accurate and efficient diagnoses.Frequently Asked Questions

Q1. How big is the Deep Learning Market?Ans. The global Sanger Sequencing Market was valued at USD 1.9 Billion in 2022 and it is anticipated to grow up to USD 13.4 Billion by 2032, at a CAGR of 21.4% during the forecast period.Q2. What is the Sanger Sequencing Market growth rate?Ans. The growth rate of the Sanger Sequencing Market is 21.4%Q3. Which region holds a major market share for the market?Ans. North America holds a major market share of the Sanger Sequencing Market in 2022.Q4. Which segment accounted for the largest Sanger Sequencing Market share?Ans. By end-use, the research institute segment accounted for the largest Sanger Sequencing Market share.Q5. Who are the key players in the kidney stones management market?Ans. The global Sanger Sequencing Market report includes players such Thermo Fisher Scientific Inc (U.S.), Source BioScience (U.K.), GenScript (U.S.), LGC Limited (U.K.), CeMIA (U.S.),, Quintara Biosciences (U.S.), GenHunter Corporation (U.S.), GENEWIZ (U.S.), , Nucleics (U.K.), SciGenom Labs Pvt. Ltd (India), Microsynth AG (Switzerland), Eurofins Scientific (Luxembourg), LGC Limited (U.K.), among others.Q6. What are the factors driving the Sanger Sequencing Market growth?Ans. The major factors driving the growth of the market are the rapid advancements in sequencing technology and bioinformatics have enabled the identification of DNA variations. These advancements also determine variants associated with increased risk for disease.Q7. What are the key growth strategies of Sanger Sequencing Market players?Ans. The key growth strategies of Sanger Sequencing Market players are product launch and product approval.Q8. Which region will provide more business opportunities for the Sanger Sequencing Market during the forecast period?Ans. The Asia-Pacific region will provide more business opportunities for the Sanger Sequencing Market during the forecast period.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.